Ernst & Young 2022 Beyond Borders Texas Report

This Texas addendum to the 32nd edition of our Beyond borders report provides a closer look at the biotechnology (biotech) industry’s noteworthy performance in the country’s second largest state, which has long been an innovation hub for tech, energy and other industries. Despite challenges around the same disruptive forces that have impacted every sector across the globe, Texas biotech has seen upsurges in the number of biotechs that have gone public, private company investment and the impact of the state’s Cancer Prevention & Research Institute of Texas (CPRIT), which provides crucial grants for leading cancer research and prevention efforts.